GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Eflornithine - IWILFIN

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

IWILFIN / Eflornithine oral

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
IWILFIN: use the published renal BSA table, not automatic per-dose halving

The official table includes an asymmetric morning/evening band. Its tablet schedule is stored as published rather than generated by dividing each usual administration.

Before applying: Confirm BSA band and source renal units; apply the table rather than a percentage alone.

Also check: IWILFIN: use the published renal BSA table, not automatic per-dose halving

Official source

Eflornithine - IWILFIN

Product / population
Adult and pediatric high-risk neuroblastoma indication; oral tablets. BSA and renal-function assessment are distinct inputs.
Renal measure
Label prints eGFR <30 mL/min without indexing clarification; dosage bands use BSA in m2.

These are the label table values, not app-calculated halves of individual doses.

Renal dosing, restrictions and evidence limits

For severe impairment (eGFR <30), section 2.3 Table 2 specifies these oral regimens by BSA in m2:

BSA (m2)Oral dose for eGFR <30 (source units: mL/min)
>1.5384 mg twice daily
0.75 to 1.5384 mg in the morning and 192 mg in the evening
0.5 to <0.75192 mg twice daily
0.25 to <0.5192 mg once daily

No regimen below BSA 0.25 is supplied in this table. Moderate impairment warrants close monitoring for liver toxicity, myelosuppression and hearing loss.

Source revision: Prescribing information revised 11/2024. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6716d8cc-66e6-4cee-935c-ccb85ed984f5

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Eflornithine - IWILFIN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult and pediatric high-risk neuroblastoma indication; oral tablets. BSA and renal-function assessment are distinct inputs.

Renal method: Label prints eGFR <30 mL/min without indexing clarification; dosage bands use BSA in m2.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - IWILFIN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult and pediatric high-risk neuroblastoma relapse-risk reduction after qualifying prior therapy; oral IWILFIN, not topical eflornithine.

Renal method: Source prints eGFR in mL/min without a BSA denominator. BSA determines the tablet regimen separately.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dose table scope

IWILFIN: use the published renal BSA table, not automatic per-dose halving

The official table includes an asymmetric morning/evening band. Its tablet schedule is stored as published rather than generated by dividing each usual administration.

How to use this: Confirm BSA band and source renal units; apply the table rather than a percentage alone.

GlobalRPh RX List - IWILFINEflornithine - IWILFIN

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeEflornithine - IWILFINGlobalRPh RX List - IWILFIN
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/iwilfin-drug/

Exact product and population

Adult and pediatric high-risk neuroblastoma relapse-risk reduction after qualifying prior therapy; oral IWILFIN, not topical eflornithine.

RDM44-SCOPE-eflornithine-iwilfin · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Eflornithine - IWILFIN

Open original reference

Open / share this exact local source

DailyMed / USWM, LLC · Adult and pediatric high-risk neuroblastoma indication; oral tablets. BSA and renal-function assessment are distinct inputs.

Renal method: Label prints eGFR <30 mL/min without indexing clarification; dosage bands use BSA in m2.
Source date: Prescribing information revised 11/2024.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For severe impairment (eGFR <30), section 2.3 Table 2 specifies these oral regimens by BSA in m2:

BSA (m2)Oral dose for eGFR <30 (source units: mL/min)
>1.5384 mg twice daily
0.75 to 1.5384 mg in the morning and 192 mg in the evening
0.5 to <0.75192 mg twice daily
0.25 to <0.5192 mg once daily

No regimen below BSA 0.25 is supplied in this table. Moderate impairment warrants close monitoring for liver toxicity, myelosuppression and hearing loss.

RDM44-official-eflornithine-iwilfin-de58dfefbc-C1 · Source locator: Section 2.3, Table 2, lines 304-313; section 8.5, lines 538-540.

Source-specific limits

These are the label table values, not app-calculated halves of individual doses.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6716d8cc-66e6-4cee-935c-ccb85ed984f5
Retrieved
2026-09-08
Exact label title
Eflornithine - IWILFIN
DailyMed Set ID
6716d8cc-66e6-4cee-935c-ccb85ed984f5
Labeler
USWM, LLC
DailyMed page updated
2026-03-26
Label revision
Prescribing information revised 11/2024.
Renal-function method
Label prints eGFR <30 mL/min without indexing clarification; dosage bands use BSA in m2.
Source date/version
Prescribing information revised 11/2024.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
5904cca72b8649f0ed9867744109ae78d4cf97a57912410b777ff731d06ea60b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - IWILFIN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult and pediatric high-risk neuroblastoma relapse-risk reduction after qualifying prior therapy; oral IWILFIN, not topical eflornithine.

Renal method: Source prints eGFR in mL/min without a BSA denominator. BSA determines the tablet regimen separately.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For eGFR <30, the source directs a 50% reduction using its renal BSA table. Moderate impairment requires closer surveillance for hepatotoxicity, myelosuppression and hearing loss. A percentage alone is not a complete tablet schedule; the separately stored official table preserves its asymmetric morning/evening band.

RDM44-rxlist-eflornithine-iwilfin-721d59deb1-C1 · Source locator: Section 2.3 and Renal Impairment, lines 45-49 and 313.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/iwilfin-drug/
Retrieved
2026-09-08
Renal-function method
Source prints eGFR in mL/min without a BSA denominator. BSA determines the tablet regimen separately.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ebc1a7b8b88082bd06bbfa49df987fb3728b5025116ac1a55887ed306783b3ce

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/iwilfin-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
d67c19fa32b32a1e48f08cbbaf3afda6342bdece3eec501eba587e540d662864
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report